Загрузка...
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-A...
Сохранить в:
| Опубликовано в: : | Pharmaceutics |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7594083/ https://ncbi.nlm.nih.gov/pubmed/33081166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12100977 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|